IL4R and cancer: In addition, a hybrid peptide (IL-4Rα-lytic) containing a target moiety to bind to IL-4Rα and a cellular toxic lytic peptide that selectively kills cancer cells showed anticancer potential in pancreatic cancer cell lines expressing IL-4Rα and in a xenograft mice model of BXPC-3 cells [106].